M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating mutations in KIT (exons 9/11) drive approximately 80% of gastrointestinal stromal tumors (GIST).
• Imatinib is a first-line therapy for advanced GIST, but resistance frequently develops due to secondary KIT mutations.
• Existing later-line therapies offer incomplete coverage of resistance mutations and limited clinical benefit.

Purpose of the Study:

• To introduce M4205 (IDRX-42), a novel kinome-selective KIT inhibitor designed to overcome imatinib resistance in GIST.
• To evaluate the preclinical efficacy and kinase selectivity profile of M4205 against KIT driver and resistance mutations.

Main Methods:

• Preclinical evaluation of M4205 in GIST models harboring oncogenic KIT driver mutations.
• Assessment of M4205 efficacy in preclinical GIST models with various secondary KIT resistance mutations.
• Comparative analysis of M4205's kinase selectivity profile against standard of care and investigational agents.

Main Results:

• M4205 demonstrated superior antitumor activity compared to imatinib in preclinical GIST models with KIT driver mutations.
• M4205 exhibited clinically relevant efficacy across a spectrum of preclinical GIST models with diverse secondary KIT resistance mutations.
• M4205 possesses a superior kinase selectivity profile compared to existing and investigational therapies.

Conclusions:

• M4205 (IDRX-42) represents a promising therapeutic candidate for GIST, effectively targeting both primary driver and secondary resistance mutations in KIT.
• The superior preclinical efficacy and selectivity profile of M4205 warrant its further investigation in clinical trials for GIST patients.
• A Phase 1 first-in-human study of IDRX-42 is currently underway to assess its safety and efficacy in GIST participants.